UNSPSC 51273302: Euprocin

This classification denotes an anesthetic agent with the molecular formula C24H34N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KRZ086R2VC, chemically known as 10,11-dihydro-6-(3-methylbutoxy)cinchonan-9-ol but generally known as euprocin, which bears US NIH Compound Identifier 14764. European Medicines Agency schedules Euprocin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07352MIG.

UNSPSC 51273302 Euprocin is a Commodity code covering pharmaceutical products—specifically naloxone, drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products—that state and local health agencies, cooperative purchasing alliances, and public health departments procure for community health initiatives, emergency response, and general pharmaceutical distribution. The work involves vendor selection for supply of FDA-compliant pharmaceutical products with specified National Drug Codes, compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, and delivery through authorized wholesaler networks or direct to public health facilities. Issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving multiple states including Oregon). Vendors must maintain commercial general liability coverage, workers' compensation insurance, and network security and privacy liability coverage; demonstrate pricing flexibility through multiple net-price formats or WAC-minus structures; and comply with E-Verify and drug-free workplace requirements where applicable.

Recent activity spans Florida, Texas, and the Upper Midwest. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, as preliminary market research on direct-to-manufacturer prescription programs serving self-insured state employee and retiree plans. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 on January 20, 2026, to establish multiple-award contracts for generic pharmaceuticals and OTC products distributed across participating state and local facilities across multiple states, with proposals due March 26, 2026; evaluation weighted 75 percent on price competitiveness and 25 percent on administrative compliance, cGMP certification, EDI capability, and pricing format flexibility. No specific budget ranges or set-aside designations appear in the available solicitation materials.